HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

AstraZeneca aims for a new blockbuster run in cardio disease

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.

By PharmaVoice · Jun 1, 2026 · via PharmaVoice
AstraZeneca aims for a new blockbuster run in cardio disease

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Eisai whips up Alzheimer's dietary guidance to expand nutrition program beyond cancer
The WeekFiercePharma ↗
Eisai whips up Alzheimer's dietary guidance to expand nutrition program beyond cancer
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease an…
Jun 2, 2026
Praxis pauses one of its seizure programs after phase 2 fail
The WeekFierceBiotech ↗
Praxis pauses one of its seizure programs after phase 2 fail
Praxis Precision Medicines' epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to su…
Jun 2, 2026
Abivax’s Phase 3 Triumph Turns Risk Event as Cancer Cases Emerge
The WeekBriefing
Abivax’s Phase 3 Triumph Turns Risk Event as Cancer Cases Emerge
Obefazimod delivered industry-leading remission rates in ulcerative colitis, but new cancer cases wiped out th…
Jun 2, 2026